Medical Treatment of Primary Internal Hemorrhoidal and External Hemorrhoidal Disease

Hendro Sudjono Yuwono^1,

¹Division of Vascular Surgery, Department of Surgery, Padjadjaran University, Jalan Eijkman, Bandung, Indonesia

Cite this paper:
Hendro Sudjono Yuwono. Medical Treatment of Primary Internal Hemorrhoidal and External Hemorrhoidal Disease. Global Journal of Surgery. 2014; 2(3):45-48. doi: 10.12691/js-2-3-4

Abstract

The aim of this study was to assess the medical treatment in comparison with hemorrhoidectomy in the management of primary grade-4 internal hemorrhoidal disease (IH) and external hemorrhoidal disease (CH). Group I (medical treatment): 127 patients (59 IH, 68 CH) were prospectively collected and medically treated using oral tablet of micronized purified flavonoid fraction (MPFF) containing 450 mg of diosmin and flavonoids expressed as 50 mg hesperidin, with dosage of 6 tablet per day for 4 days, 4 tablet per day for 3 days, and 2 tablet per day until the signs and symptoms clinically disappear or the end of observation time of 6 weeks. Group II (hemorrhoidectomy): 119 post-hemorrhoidectomy patients (50 IH and 69 CH) were observed with respect to postoperative bleeding, pain, urinary retention, soiling, constipation, recurrence. Statistical calculation using chi-square test to compare the sign and symptom of Group I and Group II. In Group I: the hemorrhoidal piles, bleeding, pain and oozing were progressively decreasing, and all complaints finally disappeared between 1 and 6 weeks without any MPFF’s adverse reaction. In Group II: postoperative bleeding, pain, soiling, urinary retention, and constipation were noted. It showed as ignificant outcome in Group I in comparison with Group II (bleeding, p=0.012; pain, p=0.000), soiling, urinary retention, anal stenosis and constipation.

Keywords:
internal hemorrhoidal disease external hemorrhoidal disease medical treatment hemorrhoidectomy flavonoid

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	GrayH. Anatomy of the Human Body.27th.Ed. Lea & Febiger. Philadelphia. 1965: 757-758.
[2]	Storer EH, Goldberg SM, Nivatvongs S.Colon, Rectum and Anus. In: Schwartz SI. Editor. Principles of Surgery. 3rd Ed.McGraw-Hill Book Company, New York, 1979: 1237-39.
[3]	KeighleyMRB, Williams NS. Hemorrhoidal disease. In: KeighleyMRB, WilliamsNS. Surgery of the anus, rectum and colon. WB Saunders Company Ltd. London. 1993. p. 295-363.
[4]	Corman, ML. Colon and rectal surgery. 3rd.edition. JB Lippincott, Philadelphia. 1993. p. 54-78.
[5]	Schwartz SI, Shires GT, Spencer FC, Daly JM, Fischer JE, Galloway AC.Principles of Surgery. Companionh and book. New York: McGraw-Hill. 1999: 657-8.
[6]	Barnett, JL. Anorectal diseases. In: Yamada T.(Editor).Textbook of Gastroenterology. Vol. 2 Lippincott Williams & Wilkins, Philadelphia. 1999. pp. 2083-6.
[7]	Godeberge P. Daflon 500mg is significantly more effective than placebo in the treatment of hemorrhoids. Phlebology. 1992; 7(suppl 2): 61-63.
[8]	Katsenis K. Micronized Purified Flavonoid Fraction (MPFF): A Review of its Pharmacological Effects, Therapeutic Efficacy and Benefits in the Management of Chronic Venous Insufficiency. Current Vascular Pharmacology, 2005, 3: 1-9
[9]	Cospite M. Double-blind, placebo-controlled evaluation of clinical activity and safety of Daflon 500 mg in the treatment of acute hemorrhoids. Angiology 1994; 45 (6,pt.2):566-573.
[10]	Buckshee K, Takkar D, Aggarwal N. Micronized flavonoid therapy in internal hemorrhoids of pregnancy. Int J Gynaecol Obstet 1997; 57: 145-151.
[11]	Bouskela E, Donyo KA, Verbeuren TJ. Effects of Daflon 500mg on increased microvascular permeability. Int J Microcirc (1994)14 (suppl 1):79.
[12]	Jean T, Bodinier MC. Mediators involved in inflammation: effects of Daflon 500 mg on their release. Angiology 1994; 45: 554-8.
[13]	Labrid C. Pharmacologic properties of Daflon 500 mg.Angiology 1994. 45: 524-30.
[14]	Lyseng-Williamson KA, Perry, CM. Micronised Purified Flavonoid Fraction: A Review of its use in Chronic Venous Insufficiency, Venous ulcers and Hemorrhoids. Drugs. 2003; 63: 71-100.
[15]	Lumb KJ, Colquhoun PHD, Malthaner R, Jayaraman S. Conventional surgical hemorrhoidectomy results in fewer recurrences than stapled hemorrhoidopexy. Cochrane Database of Systematic Reviews 2006, Issue 4.
[16]	Istiqomah. The treatment of primary hemorrhoidal disease without surgery. Department of Pharmacy, Institute of Technology Bandung. 2014.